Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Xiong, Jia; Wang, Hui; Wang, Qingqing

doi:10.1002/adbi.201900311

Cited by 9 publications

(9 citation statements)

References 204 publications

(212 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor microenvironment (TME) is a multifaceted cytosolic environment that both limits tumor development (25)(26)(27) and plays a key role in tumor progression and therapeutic response (28)(29)(30)(31). In lung adenocarcinoma (LUAD), they evaluated the correlation between the m6A-related lncRNA model and immunotherapy biomarkers, and the m6A-based classifier index can be used as a predictor of TIDE and TMB (32).…”

Section: Introductionmentioning

confidence: 99%

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

Gao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Gefitinib has shown promising efficacy in the treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Molecular biomarkers for gefitinib metabolism-related lncRNAs have not yet been elucidated. Here, we downloaded relevant genes and matched them to relevant lncRNAs. We then used univariate, LASSO, and multivariate regression to screen for significant genes to construct prognostic models. We investigated TME and drug sensitivity by risk score data. All lncRNAs with differential expression were selected for GO/KEGG analysis. Imvigor210 cohort was used to validate the value of the prognostic model. Finally, we performed a stemness indices difference analysis. lncRNA-constructed prognostic models were significant in the high-risk and low-risk subgroups. Immune pathways were identified in both groups at low risk. The higher the risk score the greater the value of exclusion, MDSC, and CAF. PRRophetic algorithm screened a total of 58 compounds. In conclusion, the prognostic model we constructed can accurately predict OS in NSCLC patients. Two groups of low-risk immune pathways are beneficial to patients. Gefitinib metabolism was again validated to be related to cytochrome P450 and lipid metabolism. Finally, drugs that might be used to treat NSCLC patients were screened.

show abstract

Section: Introductionmentioning

confidence: 99%

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

Gao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Tumor immunotherapy is an incredibly innovative treatment for cancer today, which has the advantages of stronger targeting and fewer side effects Lin et al, 2020;Tan et al, 2020;Xu et al, 2020;Wu et al, 2021;Xu et al, 2022). Although it has incomparable advantages compared with other traditional therapies, there are still problems of poor efficacy and drug resistance Dey et al, 2021;Repellin et al, 2021;Xiong et al, 2021) T cells and IFN-γ expression are positively correlated with the treatment prognosis of cancer patients. IFN-γ released by CD8 (+) T cells inhibits the expression of system Xc-, SLC3A2 and SLC7A11, thus blocking the uptake of cystine by tumor cells.…”

Section: Ferroptosis and Tumor Immunotherapymentioning

confidence: 99%

The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?

Tan

Kong

Xian

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Ferroptosis, as a newly discovered non-apoptotic cell death mode, is beginning to be explored in different cancer. The particularity of ferroptosis lies in the accumulation of iron dependence and lipid peroxides, and it is different from the classical cell death modes such as apoptosis and necrosis in terms of action mode, biochemical characteristics, and genetics. The mechanism of ferroptosis can be divided into many different pathways, so it is particularly important to identify the key sites of ferroptosis in the disease. Herein, based on ferroptosis, we analyze the main pathways in detail. More importantly, ferroptosis is linked to the development of different systems of the tumor, providing personalized plans for the examination, treatment, and prognosis of cancer patients. Although some mechanisms and side effects of ferroptosis still need to be studied, it is still a promising method for cancer treatment.

show abstract

“…Comprehensive research has described specific cellular and molecular events that may cause tumor cells to escape immune surveillance, including those involving tumorinduced myeloid cell-mediated immunosuppression [50].…”

Section: Cancer Progressionmentioning

confidence: 99%

“…Comprehensive research has described specific cellular and molecular events that may cause tumor cells to escape immune surveillance, including those involving tumor-induced myeloid cell–mediated immunosuppression [ 50 ]. Multiple studies indicate that tumor-infiltrating myeloid cells accelerate cancer growth and support angiogenesis, metastasis, and therapeutic resistance after their conversion into potent immunosuppressive cells.…”

Section: The Role Of Chronic Inflammation In Different Stages Of Carcinogenesismentioning

confidence: 99%

Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression—3PM pathways

et al. 2021

View full text Add to dashboard Cite

Inflammation is an essential pillar of the immune defense. On the other hand, chronic inflammation is considered a hallmark of cancer initiation and progression. Chronic inflammation demonstrates a potential to induce complex changes at molecular, cellular, and organ levels including but not restricted to the stagnation and impairment of healing processes, uncontrolled production of aggressive ROS/RNS, triggered DNA mutations and damage, compromised efficacy of the DNA repair machinery, significantly upregulated cytokine/chemokine release and associated patho-physiologic protein synthesis, activated signaling pathways involved in carcinogenesis and tumor progression, abnormal tissue remodeling, and created pre-metastatic niches, among others. The anti-inflammatory activities of flavonoids demonstrate clinically relevant potential as preventive and therapeutic agents to improve individual outcomes in diseases linked to the low-grade systemic and chronic inflammation, including cancers. To this end, flavonoids are potent modulators of pro-inflammatory gene expression being, therefore, of great interest as agents selectively suppressing molecular targets within pro-inflammatory pathways. This paper provides in-depth analysis of anti-inflammatory properties of flavonoids, highlights corresponding mechanisms and targeted molecular pathways, and proposes potential treatment models for multi-level cancer prevention in the framework of predictive, preventive, and personalized medicine (PPPM / 3PM). To this end, individualized profiling and patient stratification are essential for implementing targeted anti-inflammatory approaches. Most prominent examples are presented for the proposed application of flavonoid-conducted anti-inflammatory treatments in overall cancer management.

show abstract

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Cited by 9 publications

References 204 publications

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?

Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression—3PM pathways

Contact Info

Product

Resources

About